Citi Sticks to Their Buy Rating for Edwards Lifesciences (EW)
Citi analyst Joanne Wuensch reiterated a Buy rating on Edwards Lifesciences (EW) and set a $110 price target. The article notes other analyst views including J.P. Morgan Buy and Canaccord Genuity Hold. It cites EW quarterly revenue of $1.74B and net profit of $241.9M for the quarter ended June 30, versus $1.53B revenue and $329.8M net profit a year earlier.
How this was made
The 30-second read
Why it matters
This is primarily a sentiment and positioning input from a sell-side reiteration. Without new guidance, trial data, or a corporate event, it is more likely to affect short-term trading flows than to change the fundamental outlook.
Market read
A bullish rating reiteration with a stated target, but no new fundamental disclosure, suggests modest incremental impact.
What to watch
The piece does not provide the thesis behind the $110 target or any new operational update, so traders may discount it versus catalysts like guidance, product/regulatory news, or updated insider filings.
Background
Citi’s analyst Joanne Wuensch reiterated a Buy rating on Edwards Lifesciences and set a $110 price target; the article references other sell-side stances and prior quarter results.
Ticker impact
Citi analyst Joanne Wuensch reiterated a Buy on Edwards Lifesciences and set a $110 price target, alongside cited recent earnings figures.
Near-term sentiment support is possible, but magnitude is likely limited because the piece is primarily an analyst reiteration rather than a new earnings or guidance event.
A reiterated Buy and stated $110 target can influence positioning, yet the article does not disclose new guidance, trial results, contracts, or regulatory actions. It also references earnings numbers without indicating they are newly released in this article.
Market effects
Limited sector read-through; this is a single-name rating reiteration within healthcare.
No clear regional spillover beyond US healthcare sentiment.
No global catalyst described.
Counterpoint
The article also notes Canaccord maintained a Hold and that insider sentiment is negative, which could offset the bullish rating.
Key entities
- companyEdwards Lifesciences
Subject of the article, rated Buy by Citi with a $110 price target; also referenced other analyst ratings and insider selling.
- analyst_firmCiti
Reiterated Buy rating and set the $110 price target for EW.
- analyst_firmCanaccord Genuity
Maintained a Hold rating on EW as of August 3 (per the article).
